GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » Gross Margin %

Yubo International Biotech (Yubo International Biotech) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Yubo International Biotech's Gross Profit for the three months ended in Mar. 2024 was $0.00 Mil. Yubo International Biotech's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Yubo International Biotech's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Yubo International Biotech's Gross Margin % or its related term are showing as below:

YBGJ' s Gross Margin % Range Over the Past 10 Years
Min: 50.96   Med: 67.63   Max: 91.58
Current: 80.44


During the past 4 years, the highest Gross Margin % of Yubo International Biotech was 91.58%. The lowest was 50.96%. And the median was 67.63%.

YBGJ's Gross Margin % is ranked better than
90.5% of 800 companies
in the Medical Devices & Instruments industry
Industry Median: 52.66 vs YBGJ: 80.44

Yubo International Biotech had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Yubo International Biotech was 0.00% per year.


Yubo International Biotech Gross Margin % Historical Data

The historical data trend for Yubo International Biotech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yubo International Biotech Gross Margin % Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross Margin %
91.58 66.00 50.96 69.26

Yubo International Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.94 - 80.19 81.82 -

Competitive Comparison of Yubo International Biotech's Gross Margin %

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yubo International Biotech's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Gross Margin % falls into.



Yubo International Biotech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Yubo International Biotech's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0.4 / 0.605
=(Revenue - Cost of Goods Sold) / Revenue
=(0.605 - 0.186) / 0.605
=69.26 %

Yubo International Biotech's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0 / 0.003
=(Revenue - Cost of Goods Sold) / Revenue
=(0.003 - 0) / 0.003
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Yubo International Biotech  (OTCPK:YBGJ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Yubo International Biotech had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Yubo International Biotech Gross Margin % Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yubo International Biotech (Yubo International Biotech) Business Description

Traded in Other Exchanges
N/A
Address
31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.
Executives
Lina Liu 10 percent owner, officer: CFO, Treasurer and Secretary MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui director MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun director, officer: President and CEO MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Yang director MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth director C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc 10 percent owner 8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica officer: Treasurer and Secretary C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff director, officer: Chairman, President, CSO C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman director C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler director C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech (Yubo International Biotech) Headlines

No Headlines